Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

te effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

About Non-GAAP Financial Measures To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and non-GAAP Financial Data" set forth at the end of this press release.

The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial meas
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... CSM, a leading clinical trial supply company, today announced that Michael ... extensive background in financial management and accounting, bringing over 20 years of experience in ... will oversee all financial areas of the company to both strengthen CSM’s financial strategy ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study ... insights into how virulent fungi adapt through genetic modifications to fight back against ... leaves them temporarily weakened. These insights may provide clues to new ways to ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Catholic Health Initiatives, (CHI) Institute for Research and ... have announced a joint strategic partnership to focus ... community hospitals across their system. ... clinical R&D and molecular diagnostics laboratory that supports ...
... (Nasdaq: LIFE ), a provider of innovative ... bioenergy crop company, today announced they have completed sequencing the ... SOLiD™ 4.0 System by Life Technologies. The sequence ... crop and advances its development as a high yielding, low-cost ...
... a global leader in material science and high-performance polymer ... 6 languages: English, Chinese, French, German, Japanese, and Spanish. ... Account Managers and modified customer support hours to better ... for download at http://www.zeusinc.com . ...
Cached Biology Technology:BioFortis and Catholic Health Initiatives' Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine 2BioFortis and Catholic Health Initiatives' Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine 3Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 2Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 3Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 4Zeus Catalog Available in Six Languages 2
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... The National Institute of Neurological Disorders and Stroke (NINDS), ... a three-year, $900,000 grant to the Center for Biomedical ... The grant will fund the center,s biomarker research in ... detect changes in brain function and biochemistry. Led ...
... February 14, 2013 The 18th century natural philosopher ... as a consequence of the cumulative effort, across generations, ... view of evolution was largely abandoned with the advent ... most important traits and many medical illnesses across generations. ...
... assortment of amphibian species living in a pond, the more ... a parasitic infection that can cause severe deformities, including the ... the University of Colorado Boulder. The findings, published ... idea that greater biodiversity in larger-scale ecosystems, such as forests ...
Cached Biology News:NIH funds research to identify Parkinson's biomarkers 2NIH funds research to identify Parkinson's biomarkers 3Life experiences put their stamp on the next generation: New insights from epigenetics 2CU-Boulder amphibian study shows how biodiversity can protect against disease 2CU-Boulder amphibian study shows how biodiversity can protect against disease 3CU-Boulder amphibian study shows how biodiversity can protect against disease 4
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: